Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · Chief Executive Officer | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,050,249 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 1,000 · Balance 1,074,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 2,000 · Balance 1,072,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 9,300 · Balance 1,062,949 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 9,900 · Balance 1,053,049 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 2,800 · Balance 1,050,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 27 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 27 F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 213,250 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 213,250 F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 71,644 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 71,644 F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantPerformance-based Restricted Stock Units · Derivative | 213,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-017566 · doc1.xml · derivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,112 Underlying: Class A Common Stock · 213,112 shares Expires 2026-09-14 F2 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 142,075 | $0.00 Strike: $33.67 | $0.00 |
DisclosureSEC source: 0001567619-22-017566 · doc1.xml · derivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,075 Underlying: Class A Common Stock · 142,075 shares Expires 2032-09-14 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001567619-22-017433 · doc1.xml · derivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,035 Underlying: Class A Common Stock · 11,500 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, originally for 300,000 shares, of which 258,965 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 11,500 | $1.20 | $13,800.00 |
DisclosureSEC source: 0001567619-22-017433 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,715 | $35.19 | $95,544.38 |
DisclosureSEC source: 0001567619-22-016678 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,102 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 02, 2022 Filed Jun 9, 2022 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 1,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012617 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,487 F1 · ownership.nature: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,656 | $48.76 | $129,516.12 |
DisclosureSEC source: 0001567619-22-011714 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,817 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (Right to Buy) · Derivative | 146,827 | $0.00 Strike: $69.56 | $0.00 |
DisclosureSEC source: 0001567619-22-007438 · doc1.xml · derivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,827 Underlying: Class A Common Stock · 146,827 shares Expires 2032-03-22 F4 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 58,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007438 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,473 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 551 | $78.60 | $43,308.77 |
DisclosureSEC source: 0001567619-22-005521 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,742 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,038 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-22-003272 · doc1.xml · derivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,521 Underlying: Class A Common Stock · 3,038 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · derivative.exercise_date: This option, originally for 145,786 shares, of which 103,265 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,397 | $91.04 | $218,227.91 |
DisclosureSEC source: 0001567619-22-003272 · doc1.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913,293 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $90.765 to $91.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,503 | $90.30 | $406,617.75 |
DisclosureSEC source: 0001567619-22-003272 · doc1.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,690 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $89.76 to $90.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,200 | $89.19 | $374,590.44 |
DisclosureSEC source: 0001567619-22-003272 · doc1.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,193 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $88.66 to $89.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $88.17 | $79,349.49 |
DisclosureSEC source: 0001567619-22-003272 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,393 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $87.64 to $88.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,038 | $11.48 | $34,876.24 |
DisclosureSEC source: 0001567619-22-003272 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,037 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · derivative · entry 11 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,559 Underlying: Class A Common Stock · 3,037 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F11 · derivative.exercise_date: This option, originally for 145,786 shares, of which 100,227 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $145.33 | $72,663.00 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,255 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $145.19 to $145.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,400 | $144.78 | $202,694.52 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,755 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $144.185 to $145.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $143.11 | $100,178.75 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,155 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $142.99 to $143.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,932 | $141.72 | $415,516.88 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,855 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $141.38 to $142.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,368 | $140.96 | $756,662.54 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,787 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.38 to $141.375. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,100 | $139.82 | $433,444.17 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,155 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $139.33 to $140.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $138.86 | $138,863.60 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,255 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.29 to $139.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,037 | $11.48 | $34,864.76 |
DisclosureSEC source: 0001567619-22-000817 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 00:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 56,363 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001567619-21-022725 · doc1.xml · derivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,535 Underlying: Class A Common Stock · 56,363 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, originally for 300,000 shares, of which 247,465 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 00:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 56,363 | $1.20 | $67,635.60 |
DisclosureSEC source: 0001567619-21-022725 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 934,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 31, 2021 00:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-022725 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,138 F1 · ownership.nature: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,037 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · derivative · entry 14 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,596 Underlying: Class A Common Stock · 3,037 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F12 · derivative.exercise_date: This option, originally for 145,786 shares, of which 97,190 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 5,209 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · derivative · entry 13 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,323 Underlying: Class A Common Stock · 5,209 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F11 · derivative.exercise_date: This option, originally for 250,000 shares, of which 196,677 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 754 | $148.60 | $112,043.04 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,855 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $148.545 to $148.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,370 | $147.96 | $350,673.50 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,609 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $147.4621 to $148.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,480 | $147.05 | $952,882.06 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,979 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $146.45 to $147.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 571 | $145.79 | $83,247.40 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,459 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $145.34 to $146.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 672 | $144.27 | $96,949.64 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,030 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $144.00 to $144.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,187 | $143.36 | $456,881.31 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,702 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $142.86 to $143.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 766 | $142.40 | $109,074.88 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,889 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $141.77 to $142.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $138.86 | $27,772.00 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,655 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,037 | $11.48 | $34,864.76 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 5,209 | $5.04 | $26,253.36 |
DisclosureSEC source: 0001567619-21-021857 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 22, 2021 Filed Nov 25, 2021 02:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 772 | $148.38 | $114,550.21 |
DisclosureSEC source: 0001567619-21-021186 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,609 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,037 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · derivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,633 Underlying: Class A Common Stock · 3,037 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F8 · derivative.exercise_date: This option, originally for 145,786 shares, of which 94,153 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 5,208 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · derivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,532 Underlying: Class A Common Stock · 5,208 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · derivative.exercise_date: This option, originally for 250,000 shares, of which 191,468 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $163.14 | $32,628.00 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,381 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,613 | $161.94 | $908,961.92 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,581 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $161.63 to $162.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,946 | $161.06 | $957,686.54 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,194 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $160.60 to $161.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,241 | $160.26 | $519,410.11 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,140 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $159.60 to $160.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,037 | $11.48 | $34,864.76 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 5,208 | $5.04 | $26,248.32 |
DisclosureSEC source: 0001567619-21-019360 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,460 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001567619-21-018030 · doc1.xml · derivative · entry 11 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,670 Underlying: Class A Common Stock · 3,460 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F10 · derivative.exercise_date: This option, originally for 145,786 shares, of which 91,116 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.